Development and Validation of Stability-Indicating RP-UPLC Method for the Determination of Methdilazine in Bulk Drug and in Pharmaceutical Dosage Form

<table class="table-group" id="tab2"><tr><td><table class="table"><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr class="thead"><td align="left">Stationary phase</td><td align="center">Dimension</td><td align="center">Observations/remarks</td></tr><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr><td align="left">Acquity BEH Phenyl</td><td align="center">(100 × 2.1) mm, 2 <i>μ</i>m</td><td align="center">Peak eluted very early with higher tailing</td></tr><tr><td align="left">Acquity BEH C8</td><td align="center">(50 × 2.1) mm, 1.7 <i>μ</i>m</td><td align="center">No retention of MDH, eluted very early</td></tr><tr><td align="left">Eclipse Plus C18, RRHD</td><td align="center">(50 × 2.1) mm, 1.8 <i>μ</i>m</td><td align="center">Peak fronting observed</td></tr><tr><td align="left">Acquity BEH C8</td><td align="center">(100 × 2.1) mm, 1.7 <i>μ</i>m</td><td align="center">Peak eluted before 1 min</td></tr><tr><td align="left">Acquity BEH C18</td><td align="center">(100 × 2.1) mm, 1.7 <i>μ</i>m</td><td align="center">Satisfactory peak shape observed</td></tr><tr class="table-tr"><td colspan="3"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

Summary of stationary phase optimization.

International Scholarly Research Notices

tab2

Table 2

Table 2: Development and Validation of Stability-Indicating RP-UPLC Method for the Determination of Methdilazine in Bulk Drug and in Pharmaceutical Dosage Form 

Table 2 | Development and Validation of Stability-Indicating RP-UPLC Method for the Determination of Methdilazine in Bulk Drug and in Pharmaceutical Dosage Form 